Research summary
The authors report PD-L1-associated immune evasion following DR5 agonism in several preclinical solid-tumor models.
Study context
DR5 agonism and PD-L1 immune evasion
Can a death-receptor intervention also induce a countervailing immune-evasion signal?
How it was studied
The authors studied DR5 agonist exposure and downstream immune-evasion signaling in the reported cell and tumor models, using molecular and functional assays described in the open-access article.
Selected findings
- The study reports PD-L1-associated immune-evasion signaling after DR5 agonist antibody exposure in tested systems.
- The article examines TNBC, ovarian and additional solid-tumor contexts rather than a single cell line.
Preclinical work; the study does not establish a patient outcome or prescribe a validated combination regimen.
Read the full project analysis → · View publication figures →
Authors
Cite this work
Tanmoy Mondal, Gururaj N Shivange, Rachisan Gt Tihagam, Evan Lyerly, Michael Battista, Divpriya Talwar, Roxanna Mosavian, Roxanna Mosavian, Karol Urbanek, Narmeen S Rashid, J Chuck Harrell, Paula D Bos, Edward B Stelow, M Sharon Stack, Sanchita Bhatnagar, Jogender Tushir-Singh (2021). Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies. EMBO molecular medicine, e12716. https://doi.org/10.15252/emmm.202012716